BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity
- 19 February 2015
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 125 (8) , 1207-1216
Abstract
Key Points: The V600E kinase-activating mutation of BRAF profoundly shapes the distinct identity of HCL among B-cell neoplasms. Clinically available BRAF and MEK inhibitors exert potent antileukemic activity in patients’ HCL cells in vitro and in vivo.Keywords
This publication has 30 references indexed in Scilit:
- Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemiaHaematologica, 2013
- Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutationBlood, 2012
- The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasmsBlood, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- BRAFMutations in Hairy-Cell LeukemiaNew England Journal of Medicine, 2011
- How I treat hairy cell leukemiaBlood, 2010
- V600E BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathwayProceedings of the National Academy of Sciences, 2009
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityProceedings of the National Academy of Sciences, 2008
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- Mutations of the BRAF gene in human cancerNature, 2002